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RepairMyelin is critical in maintaining electrical impulse conduction in the central nervous system. The
oligodendrocyte is the cell type responsible for myelin production within this compartment. The mutual
supply of trophic support between oligodendrocytes and the underlying axons may indicate why
demyelinated axons undergo degeneration more readily; the latter contributes to the neural decline in
multiple sclerosis (MS). Myelin repair, termed remyelination, occurs in acute inﬂammatory lesions in MS and
is associated with functional recovery and clinical remittances. Animal models have demonstrated that
remyelination is mediated by oligodendrocyte progenitor cells (OPCs) which have responded to chemotactic
cues, migrated into the lesion, proliferated, differentiated into mature oligodendrocytes, and ensheathed
demyelinated axons. The limited remyelination observed in more chronic MS lesions may reﬂect intrinsic
properties of neural cells or extrinsic deterrents. Therapeutic strategies currently under development include
transplantation of exogenous OPCs and promotion of remyelination by endogenous OPCs. All currently
approved MS therapies are aimed at dampening the immune response and are not directly targeting neural
processes.y Unit, Montreal Neurological
2B4. Tel.: +1 514 398 8531;
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Myelin
The rapid transduction of electrical impulses, termed action
potentials, is required for the efﬁcient function of the vertebrate
nervous system. The conduction velocity of these impulses is
maximized by the presence of an insulating layer surrounding the
axon referred to as the myelin sheath [1–3]. In the central nervous
system (CNS), the oligodendrocyte is the resident cell type respon-
sible for the production of myelin that consists of oligodendroglial
plasma membrane loops tightly wound concentrically around the
axon. Oligodendrocyte progenitor cells (OPCs) are generated in the
ventral neuroepithelium of the neural tube in early embryonic life,
more speciﬁcally from the motor neuron progenitor (pMN) domain
[4,5], and in the dorsal spinal cord and hindbrain/telencephalon of the
brain in late embryonic development and early post-natal life [6–9].
These proliferative cells migrate into the developing white matter
[10–12], exit the cell cycle, undergo differentiation into mature
oligodendrocytes, and begin to express a subset of myelin-associated
proteins [13,14]. Following the extension of ﬂat oligodendroglial
membrane sheets, there is recognition and adhesion to axonal targets
[15]. Myelin components are then synthesized and transported to the
appropriate location within the sheath, axons are wrapped, and themyelin membrane is compacted such that the cytoplasmic myelin
leaﬂets are practically fused and almost devoid of cytoplasm [16–18].
In the CNS, one oligodendrocyte can produce up to 40 myelin
segments on multiple axons. Consequently, myelinating oligoden-
drocytes produce as much as 5–50×103 μm2 of membrane a day [19].
Maintenance of this myelin membrane occurs throughout adulthood
and comprises of a continual turnover of myelin correlated with a
high level of expression of myelin genes long after the completion of
the myelination process [20,21].
Signals derived from electrically active neurons (such as growth
factors, neurotrophic factors, and electrical activity) regulate cellular
events involved in myelination and myelin gene expression in
oligodendrocytes [22–25]. Oligodendrocytes also reciprocate signals
for neurons, by producing growth factors and by inducing the
organization of the axon into speciﬁc sub-domains by controlling
the distribution of various axonal proteins [26,27]. Gaps of myelin
cause the formation of the ‘Nodes of Ranvier’, which are axonal
segments where the sodium channels that regulate electrical impulse
conduction are aggregated (Fig. 1A). Experimental models of
demyelination have indicated that the myelin sheath is crucial in
maintaining these nodal domains over the long term [28]. Myelin also
forms the ﬂanking membrane loops, termed the paranodes, which
serve to separate the nodal sodium channels from the potassium
channels concentrated in the adjacent juxtaparanodal regions
(Fig. 1A). Together, the paranodes and juxtaparanodes form the
myelin segments called the internodes. The importance of reciprocal
communication between axons and oligodendrocytes is apparent in
Fig. 1.Myelin characteristics, demyelination, and remyelination. A. Schematic of node of Ranvier organization. Nodes of Ranvier are axonal regions of concentrated sodium channels
devoid of myelin, formed between two internodes of myelin. The area adjacent to the node is termed the paranode, characterized by Caspr and paranodin expression. The area
adjacent to the paranode is termed the juxtaparanode, where the potassium channels reside. B. Upon demyelination, there is destruction of the paranode and lateral migration of
sodium channels from the nodal region. C. Remyelination is initiated by activation of OPCs, likely by inﬂammation-associated factors (i.e. IL-1β, TNFα, LIF), and chemotactic
migration towards the lesion (i.e. PDGF, bFGF, CXCL1). Differentiation into mature oligodendrocytes and remyelination is associated with an upregulation of Olig2 and Nkx2.2, and
requires both removal of myelin debris and inﬂammatory factors (i.e. IL-1β, TNFα, CXCL2). The newmyelin sheath has shorter internodes and thinner myelin loops, and may act as a
physical barrier to protect from injurious inﬂammatory molecules, or provide trophic support anew to the axon. D. Multi-potent neural stem cells (nestin+) are speciﬁed into
oligodendrocyte progenitor cells (OPCs; A2B5+, PDGFαR+, and NG2+) by exposure to sonic hedgehog (SHH) and ﬁbroblast growth factor (FGF), whereas bone morphogenic
proteins (BMPs) inhibit this speciﬁcation. This speciﬁcation involves the transcription factors Olig2, Nkx2.2, Mash1, MyT1, Nkx2.6, Gli2, and Sox 8/9/10. OPCs can differentiate into
multiple cell types including astrocytes, neurons, and Schwann cells. Differentiation along the oligodendroglial lineage to pre-oligodendrocytes/immature oligodendrocytes (O4+/
GalC+) is potentiated by the growth factor IGF-1, the cytokine CNTF, and the thyroid hormone T3, and requires the transcription factors Olig1/2, Sox10, and Nkx2.2/2.6. Conversely,
BMPs and transcription factors Sox5/6 prevent this differentiation. Differentiation into mature oligodendrocytes is associated with acquisition of myelin-related proteins, such as
myelin basic protein (MBP), myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG), oligodendrocyte–myelin glycoprotein (OMgp), and 2′,3′-cyclic
nucleotide 3′-phosphodiesterase (CNPase).
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are associated with a considerable degeneration of axons. For
instance, in multiple sclerosis (MS), oligodendrocyte loss and
demyelination are associated with progressive axonal degeneration
and neurological decline [29–31]. Recovery from relapses in MS
(remittances) can reﬂect a number of mechanisms, including the
resolution of the exaggerated inﬂammation response and consequentsparing of neural cells, the functional reorganization of nodal
components, and myelin repair (remyelination).
2. Role of remyelination in functional neural recovery
Remyelination is the default spontaneous process by which
demyelinated axons undergo ensheathment with newmyelin sheaths
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lesions has been documented to occur in MS by neuropathologic
criteria, where completely remyelinatedMS lesions are called shadow
plaques due to the intermediate levels of myelin staining intensity
[34,35]. This likely reﬂects the relative decrease in myelin thickness
and internodal length in the new myelin sheaths relative to the
original parameters of the sheath [36]. Remyelination is not only
found in inactive lesions but can also be observed in lesions with
ongoing demyelinating activity [35–37]. Remyelination in MS has also
been evidenced by magnetic resonance imaging-based criteria of
changes in magnetization transfer ratio within lesions [38]. The new
myelin sheath may either act as a protective physical barrier to
damaging inﬂammatory molecules [39], or restore trophic support to
the axon [40–42]. However, some patients demonstrate extensive
remyelination and yet clinical deterioration proceeds [43], suggesting
that remyelination alone is not always sufﬁcient in restoring function.
Demyelination in MS has been associated with a disruption of the
paranodal region, resulting in altered expression and distribution of
proteins such as neurofascin 155, contactin-associated protein
(Caspr), and paranodin, as well as ion channels [44–46]. Consequent-
ly, nodal sodium channels are then directly adjacent to juxtaparanodal
potassium channels, leading to impaired saltatory conduction of
action potentials (Fig. 1B). The remyelination process is associated
with a correct re-distribution of paranodal proteins comparable to the
developmental sequence of nodal assembly [28] (Fig. 1C). Studies
have demonstrated that sodium channel re-aggregation at the nodes
of Ranvier is an early event in remyelination that occurs prior to new
myelin sheath formation [45]. However, this aggregation of sodium
channels on a demyelinated axon just prior to remyelination may
render it more susceptible to injury [33].
3. Role of oligodendrocyte progenitor cells in remyelination
Animal models of toxin-induced demyelination have designated
the remyelination process as being mediated by newly inﬁltrated
proliferative OPCs that have differentiated into mature myelinating
phenotypes, rather than previously myelinating post-mitotic mature
oligodendrocytes within the lesion. More speciﬁcally, retroviral
tracing has indicated that proliferative cells eventually give rise to
remyelinating oligodendrocytes [47]. OPCs also remyelinate efﬁcient-
ly upon transplantation into focal demyelinated lesions [48–50].
Additionally, lesions in which there is widespread oligodendrocyte
death are characterized by a repopulation of OPCs prior to new
oligodendrocyte formation [51–53]. The role of OPCs in protecting
axonal integrity has also been highlighted in an animal model of
demyelination where depletion of these cells via X-ray irradiation
results in increased axonal swellings and decreased axonal numbers
in white matter tracts that would normally undergo remyelination
[54].
The OPCs with remyelinating potential are believed to be
randomly distributed within the CNS. However, areas that are distal
from progenitor germinal zones, such as the optic nerves, are the ﬁrst
to demonstrate impairments in the remyelination process [55]. OPCs
have been termed as stem cells of sort due to their multi-potentiality,
self-renewal potential, and rapid proliferative response to injury.
OPCs are highly proliferative, motile, bipolar cells expressing high
levels of the GT3 ganglioside A2B5, PDGF receptor alpha (PDGFαR),
and the CSPG NG2 [19]. The expression of these molecules and hence
OPC speciﬁcation are regulated by the basic helix–loop–helix (bHLH)
transcription factors Olig1, Olig2, Mammalian achate schute Homolog
1 (Mash1), and the zinc ﬁnger transcription factor Myelin transcrip-
tion factor 1 (MyT1) [52,56,57]. OPCs are also very responsive to
agents that promote their differentiation along the oligodendroglial
lineage, such as insulin-like growth factor (IGF)-1, ciliary neuro-
trophic factor (CNTF), and thyroid hormone (T3) [58,59]. Differenti-
ation requires the function of Olig1, Olig2, Nkx2.2, Nkx2.6, MyT1, andsex determining region Y box (Sox)-10 [50,56,57,60], likely due to
interaction of these transcription factors with the promoters of myelin
genes [61–63] (Fig. 1D). The directed migration of these cells to
presumptive white matter has been suggested to be mediated by the
chemo-attractant PDGF and semaphorin 3F, the chemo-repellents
netrin-1, semaphorin 3A, and the ephrins, as well as the stop-signals
CXCL1 and tenascin C [64–68]. OPCs can be identiﬁed in the adult
human brain, consisting of 5–8% of total glial cells [59]. Interestingly,
adult OPCs demonstrate slower motility, a prolonged cell cycle, and
poorer survival relative to developmental OPCs [69–71]. The restric-
tion of these cells to the oligodendroglial lineage in vivo is unlikely:
these cells were originally termed O-2A cells due to their potential to
generate both oligodendrocytes and astrocytes in vitro. In addition,
they can develop into neurons within neurogenic domains of the CNS
(i.e. hippocampus) and have the capacity to generate Schwann cells
following immune-mediated white matter injury [72]. The generation
of OPCs from differing developmental pathways likely contributes to
the heterogeneous population of OPCs observed in development [72–
74]; whether this heterogeneity exists in adulthood is unknown.
Subsets of precursors expressing varying levels and combinations of
markers do exist in adult white matter [75]. Precursors with
differential responses to growth factors can also be isolated from
the adult rat forebrain [76]. These precursor subsets may differentially
contribute to remyelination and may be under the control of distinct
regulatory mechanisms. OPCs can mature into pre-oligodendrocytes,
expressing an unidentiﬁed sulfatide recognized by the O4 antibody
[77]. Although still proliferative, these cells are non-motile likely due
to the adoption of amulti-processed complexmorphology. Once these
cells have then progressed to differentiation into immature oligoden-
drocytes, they have undergone cell cycle-arrest. They can still be
identiﬁed by the O4 antibody, yet expression of OPC markers such as
A2B5 and PDGFαR is repressed (Fig. 1D). Arborizations are elaborated
and maturity-associated markers are acquired (galactocerebroside
(GalC)) without the formation of myelin (Fig. 1D). The subsequent
ﬁnal stage of differentiation into mature oligodendrocytes comprises
of the acquisition of myelin proteins and axonal contact (Fig. 1D).
Interestingly, factors that promote survival and differentiation, such
as CNTF, are not necessarily sufﬁcient in causing myelin formation to
occur in vivo [78].
Whether mature oligodendrocytes can themselves contribute to
remyelination has been a topic of great debate. This has been negated
by the ﬁndings that these cells are post-mitotic, non-migratory, and
unable to remyelinate upon transplantation into lesions [79,80].
Mature oligodendrocytes do re-extend processes following sub-lethal
injury; however these processes are intercalated between axons and
do not ensheathe them [81].
4. Requirements for remyelination: inﬂammation-dependent OPC
activation
The ‘activation’ of OPCs is thought to be required for remyelination
to occur. This involves the adoption of a hypertrophic morphology,
increased expression of genes associated with oligodendroglial
differentiation (such as the transcription factors Olig2 and NK2
transcription factor related locus 2 (Nkx2.2)), and responsiveness to
mitogens and chemoattractants that are released from glia in the
injured tissue [56,82]. This activation process may be required to
prevent OPC differentiation in the normal intact white matter [83].
This activation response is proportional to the inﬂammatory reaction
that succeeds demyelination and is required for successful remyelina-
tion to occur in animal model systems [84,85]. Myelin debris has been
shown to be inhibitory to OPC differentiation and is phagocytosed by
reactive macrophages that have entered the lesion area [86].
Furthermore, chemokines and cytokines such as tumor necrosis factor
(TNF) α, interleukin (IL)-1β, IL-11, and Chemokine C–X–C motif
ligand (CXCL)-2 can promote OPC proliferation, differentiation, and
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which can both be foundwithinMS lesions, can release growth factors
that can affect the remyelination process [91–94]. Accordingly, the
migration and differentiation of transplanted progenitors in the
commonly used inﬂammatory model of MS, experimental autoim-
mune encephalomyelitis (EAE) corresponds to the peak of inﬂamma-
tion [95]. The pro-inﬂammatory cytokines IL-1β and TNFα
synergistically enhance OPC migration to FGF [96].
5. Animal models to study remyelination
Various animal model systems have been developed to study
different aspects of remyelination.
5.1. Lysolecithin and ethidium bromide focal injections
A common model used to study the remyelination process in the
absence of concomitant demyelination and exaggerated inﬂammation
involves focal injections of toxins such an ethidium bromide or
lysolecithin into either the spinal cord or white matter tracts of the
brain. This induces a reproducible demyelination in predeﬁned areas
of the central nervous system (CNS) by inducing cell death of
oligodendrocytes (using ethidium bromide) and myelin membrane
solubilization (using lysolecithin) at the site of injection [97–99].
These models are attractive in their succinct temporal separation
between de- and remyelination processes and the spontaneous OPC-
mediated remyelination that occurs within 4 weeks post-injection.
There are, however, confounding issues of toxin-induced axonal
damage, BBB breakdown, and moderate traumatic injury with
consequent immune cell inﬁltration at the injection site [100–102].
5.2. Oral cuprizone administration
Another commonly usedmodel involves oral administration of the
toxin cuprizone (oxalic acid bis (cyclohexylidene hydrazide)) that
induces oligodendrocyte cell death, myelin membrane vacuolization,
and demyelination in speciﬁc white matter tracts of the brain (i.e.
cerebellar peduncles, corpus callosum, and anterior commissure)
[103]. Although the mechanism of demyelination of cuprizone is
unknown, its copper chelation functions have implicated the
deregulation of copper-dependent mitochondrial functions and
resultant impairment in energy production in oligodendrocytes
[104]. Interestingly, some areas of white matter are spared from
cuprizone toxicity (i.e. spinal cord, optic nerve) suggesting regional
differences in oligodendroglial/myelin energy requirements. Follow-
ing cessation of cuprizone treatment, demyelinated lesions demon-
strate robust spontaneous remyelination [105]. OPC proliferation and
recruitment to lesion areas is initiated during the period of cuprizone-
induced demyelination, causing an overlap in demyelination and
repair processes [106]. This model is characterized by a signiﬁcant
lesional inﬁltration and reactivity of microglia and astrocytes that
likely contribute to the secretion of remyelination-promoting factors;
there is no evidence of T lymphocyte involvement or of BBB
breakdown [107].
5.3. Inﬂammatory models
As previously mentioned, the inﬂammatory process is critical in
inducing OPC activation and subsequent remyelination. Several
models of inﬂammation-induced demyelination show spontaneous
remyelination even in the presence of an exaggerated immune
response. For instance, the EAE model in which animals are
immunized against the myelin–oligodendrocyte glycoprotein
(MOG) antigen is characterized by a relapse-remitting phenotype,
however remyelination is not very extensive perhaps due to the dense
inﬁltration of macrophages andmicroglia in the lesion over prolongedperiods of time. The only indication of impressive levels of
remyelination in EAE is observed in focal models of cortical
demyelination involving immunization with subclinical doses of
MOG and injection of pro-inﬂammatory mediators [108]. Another
model, Theiler's murine encephalomyelitis (TME), consists of injec-
tion of a single-stranded ribonucleic acid (RNA) picovirus into the CNS
to induce immune-mediated oligodendroglial cell death, axonal
damage, and demyelination in the gray and white matter of the CNS
[109]. This model can be characterized by varying levels of
remyelination which renders it appropriate for testing of agents that
can potentially inhibit or enhance the myelin repair process [110].
Both these models have been used as standards for the development
and testing of therapeutic strategies for autoimmune diseases.
6. Postulates for failure of remyelination in MS
Although a limited number of MS patients have extensive
spontaneous remyelination in up to 96% of lesions [111], most
patients eventually demonstrate impaired or insufﬁcient remyelina-
tion as the disease progresses [111,112]. OPCs are increased in
numbers in actively demyelinating MS plaques, yet are depleted over
time [113–116]. Failure in remyelinationwould imply that chronically
demyelinated axons are rendered more susceptible to degeneration
and immune-attack. Indeed, chronically demyelinated plaques are
comprised of severely injured axons that are progressively cleared
over time [117,118]. Axons that have been chronically demyelinated
for long periods of time, however, can still be remyelinated under
acute inﬂammation [119]. There are a multitude of hypotheses as to
why remyelination fails in MS, which may reﬂect either changes in
environmental inputs or intrinsic pathways regulating OPC function
[120,121].
6.1. Immune-mediated injury to OPCs and new myelin sheath
A postulate that supports that former hypothesis proposes that the
new myelin sheath and OPCs are subject to immune-mediated injury
to the same degree as the initial insult to the oligodendrocytes and
myelin [121]. Post-mortem analysis of MS plaques indicates that
remyelination may be interrupted by inﬂammation [122]. In acute
demyelinating animal models with a single insult and no continuing
injury to myelin, the ensuing remyelinating is complete [123].
Antibodies recognizing progenitor cell-speciﬁc antigen (AN2) have
been identiﬁed in the CSF of relapse-remitting MS patients and could
induce OPC lysis [124].
6.2. Exhaustion of OPC source
Another proposal is that repeated demyelinating insults, as
observed in the relapse-remitting form of MS, cause an exhaustion
of the OPC source. Accordingly, recurrent demyelinating insults to the
corpus callosum with oral administration of the oligodendrocyte
toxin, cuprizone, resulted in accumulative failure in remyelination
and progressive diminishment in repopulation of mature oligoden-
drocytes [125]. However, successive demyelination of the brain stem
with ethidium bromide does not affect the efﬁciency of remyelination
nor progenitor numbers [126]. This suggests that remyelination
failure may be regionally deﬁned due to exhaustion of distinct
progenitor pools. Proliferating OPCs are rare in MS lesions suggesting
that depletion of progenitors is conceivable following repeated
episodes or extended periods of demyelination and recurrent
episodes of remyelination [116,126–128].
6.3. Glial scar in lesion
The glial scar formed within the lesion, comprised of hypertrophic
reactive astrocytes and meningeal ﬁbroblasts, likely serves to form a
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also thought to secrete factors that may inhibit OPC migration into
the scar and subsequent differentiation. For example, some plaques
with a reactive astrocytic core have high levels of CXCL1 and
ephrins at their perimeter that may impede OPC migration into the
lesion [129,130]. Also, the presence of myelin-associated debris in
the glial scar, including myelin-associated glycoprotein (MAG),
oligodendrocyte–myelin glycoprotein (OMgp), and NogoA, can
prevent axonal regeneration and inhibit OPC differentiation [133].
OPCs grown on myelin substrates in vitro show impairments in
maturation [131]. Additionally, the injection of myelin debris into a
focal demyelinated lesion prevents the remyelination that normally
succeeds [86]. The scar is also hypothesized to have upregulated
levels of other molecules inhibitory to axonal regeneration and may
render the axon unsuitable for remyelination, such as chondroitin
sulfate proteoglycans (CSPGs) and semaphorins [132]. The presence
of astrocytes within the lesion has been previously hypothesized to
be sufﬁcient to dampen the rate of remyelination via inhibition of
OPC process extension and migration [96]. Nonetheless, trans-
planted OPCs are able to repopulate astrocytic lesions and
endogenous remyelination does not occur in the adult when
astrocytes are depleted [133]. LIF released from astrocytes can
indeed promote myelin formation [25]. Some have argued that the
glial scar is not a cause of failed remyelination but rather a
consequence of it [82].6.4. Upregulation of developmental regulators of myelination
An additional hypothesis for the failure in remyelination in MS
proposes that re-expression of developmental regulators of myelina-
tion, such as Leucine rich repeat and Ig domain-containing (LINGO)-1
and polysialic acid-neural cell adhesion molecule (PSA-NCAM), may
be re-expressed on stressed axons within the lesion and repel OPCs
[134]. This is supported by the ﬁnding that non-differentiated and
non-myelinating OPCs are closely associated to the axon in some MS
lesions [135]. In addition, reactivation of theWnt signaling pathway in
MS lesions suggests that dysregulation of this pathway may
contribute to inefﬁcient myelin repair; indeed, dysregulation of this
pathway in an experimental model of demyelination interfered with
remyelination [136].6.5. Aging-related deﬁcits in inﬂammation and OPC differentiation
The remyelination process has also been shown to decline with
age in experimental animal models; this is relevant in the context of
MS that runs over several decades of life [137,138]. One explanation
could relate to prolonged exposure to inﬂammatory mediators that
induce an accumulation of neural damage over time [107]. This age-
related failure in remyelination has also been attributed to delayed
clearance of myelin debris by phagocytic macrophages, consequently
impairing OPC differentiation [123]. This is supported by studies of
MS lesions in which early lesions and periplaque white matter
(PPWM) have an increased number of OPCs (Olig2+) co-expressing
a mature oligodendrocyte marker NogoA, thereby suggesting a
differentiation block as a potential cause for remyelination failure
[116]. The aforementioned importance of inﬂammation in inducing
the activation of OPCs and resultant remyelination would also
suggest that OPCs in un-remyelinated MS lesions may still be
functional yet are not immersed in the appropriate inﬂammatory
environment that would induce differentiation [135,139]. Further-
more, studies have demonstrated that remyelination efﬁciency is
regulated by age-dependent epigenetic control of gene expression,
and dysregulation of this process may contribute to the decline in
remyelination with age [140].6.6. Temporal discordance of remyelination with inﬂammation
The slow rate of OPC repopulation of demyelinated lesions
observed in animal systems has led to the hypothesis that remyelina-
tion may be unsuccessful in MS due to a temporal discordance
between OPCmigration into the lesion and the inﬂammation required
for OPC activation that is generated from myelin breakdown [82].
Delaying OPC inﬁltration into lesions by their transplantation at a site
distal from the demyelinated area results in impaired remyelination
[121]. However, increasing progenitor recruitment to demyelinated
lesions in aged animals via PDGF upregulation in astrocytes is not
sufﬁcient in rescuing the failed remyelination process [141]. This
suggests that deﬁcits in OPC migration cannot explain the deﬁciency
in remyelination with aging.
7. Therapeutic strategies to promote remyelination
Current studies using experimental animal models of demyelin-
ation are aimed at discovering therapeutic strategies to overcome
these obstacles and to replace myelin under circumstances in which
endogenous remyelination is unsuccessful. Remyelination efﬁciency
may be improved either by supplementing the CNS with an
exogenous source of OPCs or promoting the endogenous repair
process.
7.1. Transplantation of exogenous cells with myelinating potential
Exogenous cells (such as neural stem cells, Schwann cells,
olfactory ensheathing cells, mesenchymal stem cells, and OPCs)
have been transplanted into focal demyelinated lesions to promote
remyelination. Using this therapeutic approach in the demyelinated
brain, however, is confounded by the limited migration of trans-
planted cells in the adult CNS, the availability of source material,
potential tumorigenesis, immunological incompatibility/immune-
mediated targeting of these cells, and the putative exhaustion of
transplanted cells with recurrent demyelination. The route of
administration also represents an additional dilemma; for instance,
direct parenchymal injections would be complex given the presence
of multi-focal randomly distributed lesions in MS. Other methods of
administration, such as intravenous and intra-arterial injections,
trigger functional improvement but raise the issue of tissue targeting
and distribution [142].
Nevertheless, transplantation of human OPCs has proven effective
in initiating myelin formation in dysmyelinated mutants [143,144].
Interestingly, adult CNS-derived progenitors can myelinate dysmye-
linated CNS at a relatively quicker rate than their embryonic
counterparts [145]. Transplantation of human OPCs into a leukodys-
trophy animal model has demonstrated the capacity of these cells to
integrate into whitematter, contribute to myelination, and survive for
prolonged periods of time in the host. Additionally, transplantation of
bone marrow cells and embryonic neurospheres results in ameliora-
tion of EAE pathology and clinical symptoms [146,147]. Moreover,
transplanted neurospheres can promote remyelination mediated by
cells of both endogenous and exogenous origins in EAE-afﬂicted
animals [148].
Transplantation may prove effective if the exogenous cells
functionally substituted for or stimulated endogenous remyelination
by OPCs that have intrinsic defects in remyelination-associated
processes, such as migration and differentiation. Accordingly, follow-
ing an acute demyelinating insult, transplanted cells remyelinate
lesions at a faster rate than endogenous progenitors [84,149].
Notably, repopulation of a demyelinated lesion with OPCs is not
sufﬁcient to induce remyelination [149]. Contrary to the ability of
axonal signals to induce OPC differentiation during developmental
myelination, chronically demyelinated axons in adult CNS lesions do
not promote OPC differentiation and remyelination even under
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cell transplantation approach may prove more effective as an anti-
inﬂammatory therapy given that systemic administration of CNS-
derived progenitors promotes endogenous repair via peripheral
immuno-modulation rather than through new myelin formation
[151]. Systemically applied neural stem cells distribute to the
lymphoid organs and reduce pro-inﬂammatory cytokine production
and auto-reactive cytotoxic T cell responses. Transplanted cells also
have neuroprotective properties via release of trophic factors [152].
7.2. Promoting endogenous remyelination
A parallel approach to enhance remyelination is to attempt to
promote endogenous repair. One area of interest involves the
application of growth factors that stimulate OPC responses relevant
for remyelination, such as proliferation, migration, differentiation,
and survival. In fact, the upregulation of growth factors in many
instances of trauma, including ischemia and spinal cord injury,
indicates the importance of these factors in initiating a repair process
[153,154]. Promoting oligodendroglial survival via treatment with
neurotrophic factors such as CNTF, IGF-1, and glia growth factor
(GGF)-2 has been successful in attenuating EAE pathology [155–157].
However, the repair-promoting characteristics of these factors are lost
upon targeted delivery to the CNS, suggesting peripheral mechanisms
of action [158,159]. In light of this, systemic growth factor treatment
raises the issue of non-speciﬁc effects on the immune system.
Moreover, the efﬁciency of growth factors in attenuating EAE does
not necessarily translate into successful treatment of MS patients, as
evidenced by the failed clinical trial with IGF-1[160].
An initial counter-intuitive observation that immunization of
animals with spinal cord homogenates can induce extensive remye-
lination has revealed that myelin- and oligodendrocyte-reactive
Immunoglobulin M (IgM) autoantibodies can promote endogenous
myelin repair in models of viral- or toxin-based demyelination
[161,162]. Although these antibodies bind oligodendrocytes and
white matter tracts, the mechanism of action through which repair
is enhanced is unknown. Hypotheses include antibody-dependent
cross-linking of molecules on the surface of oligodendrocytes that
initiate signaling cascades relevant for the remyelination process.
Recent studies have focused on hormonal therapy as a means of
enhancing endogenous repair mechanisms in the CNS. The observa-
tions that MS is more prevalent in females, that remission occurs
during the course of pregnancy, and that relapses increase post-
partum [163] have highlighted the importance of sex-speciﬁc factors
in regulating immune responses and repair. Pregnant murine females
have increased numbers of newly generated oligodendrocytes, OPCs,
and myelinated axons, and demonstrate enhanced remyelination
following lysolecithin-induced demyelination of the spinal cord
[138,164]. Endogenous hormone production occurs both in the
adrenal glands and in the CNS in a cholesterol-dependent manner
[165], and is hypothesized to not be sufﬁcient enough in males to
protect them from brain injury [166]. Hormones can readily penetrate
the blood–brain barrier and have neuroprotective properties. Addi-
tionally, hormones have been implicated in regulating the survival of
oligodendrocytes and myelination [167–169]. Even though hormone
receptor expression is modulated in a sex- and hormone status-
dependent manner, both male and female rats are responsive to the
neuroprotective effects of hormonal therapy [179]. Administration of
the hormone prolactin to virgin mice is sufﬁcient in reproducing the
superior remyelination observed in pregnant females [164]. Other
hormonal therapies such as the synthetic analogues estradiol and
progestin bestow neuroprotection in various CNS injury systems
including EAE [169]. Clinical trials in which non-pregnant and post-
partum relapse-remitting MS patients were treated with these
hormones demonstrated their potential application for autoimmune
disease therapy [170]. The use of hormonal therapies for MS isconfounded by their potential pro-inﬂammatory properties [171], the
risk of development of hormone-responsive cancers [166], and
putative excitotoxicity due to their actions on neurotransmitter
receptors [172].
We are entering a new era of MS-directed immunomodulatory
therapies that can not only modulate peripheral immune responses,
but can also access the CNS by virtue of their lipophilicity and may
therefore directly impact cells of the oligodendroglial lineage and
remyelination. A newly emerging sphingosine-1-phosphate analogue,
FTY720 (ﬁngolimod), was initially propelled intoMS clinical trials due
to observations of its anti-inﬂammatory properties in EAE [173–175].
FTY720 can cross the BBB and enter the brain parenchyma [176].
Microarray proﬁling has revealed that FTY720 treatment of EAE
animals results in an increase in transcript levels of myelin-related
genes and normalization of electrophysiological responses [177,178].
The efﬁcacy of FTY720 in relieving clinical disability in the later stages
of EAE where inﬂammation has subsided suggests a neuroprotective
effect [173,174,178]. Audoradiographical and microscopic analysis of
rodents that were orally administered C14-labelled FTY720 (7.5 mg/
kg) for 1 week demonstrated that the drug is concentrated in myelin
sheaths [178]. Both rodent and human OPCs and mature oligoden-
drocytes have been shown to express the sphingosine-1-phosphate
(S1P) receptor isoforms that can bind the active phosphorylated form
of FTY720 [179–184]. Studies where FTY720 was directly applied to
dissociated cultures of human and rodent OPCs and mature
oligodendrocytes demonstrate the capacity of these cells to respond
to this drug in a dose- and treatment duration-dependent manner
[182–186]. FTY720 was able to modulate process extension, differen-
tiation, migration, and survival in these cells. Application of
physiological doses of the active form of the drug to demyelinated
organotypic cerebellar slice cultures resulted in enhanced remyelina-
tion with an accompanying increase in OPC and mature oligodendro-
cyte process extension and astrocytic/microglial response [186].
Fumaric acid esters (FAE), including BG12, are intermediate products
of the citric acid cycle that are currently being evaluated in MS clinical
trials due to their immunomodulatory properties [187]. Recent
studies have suggested that FAEs may have neuroprotective proper-
ties by affecting anti-oxidative pathways in oligodendrocytes and
other glia, which may conceivably protect neural cells frommetabolic
and inﬂammatory stress [188]. FAEs have been shown to protect
myelin from immunological damage in EAE [189], yet not from
cuprizone-induced demyelination [190]. FAEs have, however, been
associated with a slight enhancement in remyelination in vivo [190].
In addition, neuropoietic cytokines (neurokines), such as leukemia
inhibitory factor (LIF), CNTF, IL-6, oncostatin-M and IL-11, are
cytokines which can regulate neural cell function. CNTF, LIF, and
oncostatin-M were identiﬁed in a screen as being associated with
enhanced myelin production [191]. Oligodendrocyte survival is
enhanced by exposure to exogenous LIF in vitro [192] and in vivo in
both chronic and relapse-remitting forms of EAE [193]. Additionally,
IL-11 is able to potentiate the survival, maturation, and myelination
potential of oligodendrocytes [90]. The production of neuropoietic
cytokines within the CNS and their accessibility to this compartment
when exogenously applied [193] highlight them as candidates for
multiple sclerosis therapy. Neurokines such as CNTF have been
detected in the cerebral spinal ﬂuid of multiple sclerosis patients
[194]; however, CNTF therapy worsened clinical conditions of treated
patients [195].
8. Conclusions
Experimental animal systems have revealed the importance of
OPCs and remyelination in reconstitution of the myelin sheath and
subsequent recovery of neural function. Analyses of MS lesions by
neuropathologic and magnetic resonance based criteria have dem-
onstrated that remyelination does occur in acute inﬂammatory
190 V.E. Miron et al. / Biochimica et Biophysica Acta 1812 (2011) 184–193lesions yet is limited in more chronic lesions, perhaps reﬂecting a
plethora of biological indices. All currently approved therapies for MS
are aimed at dampening the exaggerated immune response, are only
moderately effective at reducing the frequency of clinical relapses, do
not slow the progression of the disease, and do not directly inﬂuence
myelin and remyelination in the central nervous system. As such, the
identiﬁcation of new therapeutic factors that can protect neural cells
from injury, directly promote myelin repair, and hinder disease
progression has profound implications for the treatment of MS.
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